TFF Pharmaceuticals, Inc. (TFFP) |
|
0.945 -0.005 (-0.52%)
|
01-27 15:18 |
|
Open: |
0.9189 |
Pre. Close: |
0.9499 |
|
High:
|
0.96 |
Low:
|
0.911 |
|
Volume:
|
59,247 |
Market Cap:
|
34(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:48:29 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.17 One year: 1.31 |
| Support: |
Support1: 0.81 Support2: 0.67 |
| Resistance: |
Resistance1: 1 Resistance2: 1.12 |
| Pivot: |
1 |
| Moving Average: |
MA(5): 0.94 MA(20): 1 
MA(100): 2.34 MA(250): 4.39 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 20 %D(3): 22.1 |
| RSI: |
RSI(14): 40.2 |
| 52-week: |
High: 7.69 Low: 0.81 |
| Average Vol(K): |
3-Month: 269 (K) 10-Days: 94 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TFFP ] has closed above bottom band by 25.7%. Bollinger Bands are 77.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 42 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.96 - 0.97 |
0.97 - 0.97 |
|
Low:
|
0.9 - 0.9 |
0.9 - 0.91 |
|
Close:
|
0.93 - 0.95 |
0.95 - 0.96 |
|
Company Description |
|
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas. |
Headline News |
Tue, 24 Jan 2023
Demerara Bank loans St. Vincent Gov't funds to buy prefab homes ... - News Room Guyana
Mon, 23 Jan 2023
Billionaire Niel's NJJ Projet to challenge M6 and TF1 for French TNT ... - Reuters.com
Mon, 09 Jan 2023
TFF Pharmaceuticals (TFFP) Appoints Zamaneh Mikhak as Chief ... - StreetInsider.com
Mon, 09 Jan 2023
France stocks higher at close of trade; CAC 40 up 0.68% By ... - Investing.com
Mon, 05 Dec 2022
TFF Pharmaceuticals Chief Executive Glenn Mattes Resigns >TFFP - MarketWatch
Tue, 22 Nov 2022
TFF Pharmaceuticals (TFFP) Stock: Undefeatable To Speculative - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
36 (M) |
|
% Held by Insiders
|
2.229e+007 (%) |
|
% Held by Institutions
|
18.3 (%) |
|
Shares Short
|
735 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-3.417e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-17 |
|
Return on Assets (ttm)
|
696.7 |
|
Return on Equity (ttm)
|
-62.1 |
|
Qtrly Rev. Growth
|
195020 |
|
Gross Profit (p.s.)
|
59.68 |
|
Sales Per Share
|
-83.14 |
|
EBITDA (p.s.)
|
-1.68333e+007 |
|
Qtrly Earnings Growth
|
-1.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-31 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.02 |
|
Price to Cash Flow
|
1.67 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
698480 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
